drugset
Drugs / Tocilizumab
last change today re-read 2 minutes ago

Tocilizumab

also known as Actemra · RoActemra · TCZ · MRA · TYENNE · ActemraMR · Actmera · Atlizumab · +8 more

Monoclonal antibody targets IL6, IL6R via inhibition

Developed for
rheumatoid arthritis · COVID-19 · temporal arteritis · pneumonia · plasma cell myeloma · polyarticular juvenile idiopathic arthritis · systemic-onset juvenile idiopathic arthritis · juvenile idiopathic arthritis
+127 more · acute myeloid leukemia · cytokine release syndrome · disease of orbital part of eye adnexa · major depressive disorder · polymyalgia rheumatica · systemic sclerosis · Takayasu arteritis · hematopoietic and lymphoid cell neoplasm · interstitial lung disease · ischemic stroke · leukemia · relapsing polychondritis · severe acute respiratory syndrome · uveitis · acute chest syndrome · acute respiratory distress syndrome · adamantinous craniopharyngioma · ankylosing spondylitis · Behcet disease · breast cancer · disease related to hematopoietic stem cell transplant · end stage renal failure · generalized myasthenia gravis · graft versus host disease · malignant pancreatic neoplasm · metastatic melanoma · multicentric Castleman disease · myelodysplastic syndrome · myocardial infarction · neuromyelitis optica · non-small cell lung carcinoma · schizophrenia · sickle cell disease · viral pneumonia · acute graft versus host disease · acute leukemia · acute respiratory failure · adult-onset Still disease · anterior ischemic optic neuropathy · arthritic joint disease · autoimmune disease · B-cell chronic lymphocytic leukemia · basal cell carcinoma · bone sarcoma · brain ischemia · breast carcinoma · calciphylaxis · carcinoma of urethra · cerebral atherosclerosis · cerebral infarction · chondrocalcinosis · chronic graft versus host disease · chronic leukemia · colitis · cutaneous melanoma · cutaneous neuroendocrine carcinoma · dermatomyositis · diabetic macular edema · disease related to solid organ transplantation · disease related to transplantation · epilepsy · Erdheim-Chester disease · esophageal adenocarcinoma · familial Mediterranean fever · fever, familial lifelong persistent · fibrous dysplasia · glioblastoma · granulomatosis with polyangiitis · granulomatous mastitis · head and neck cancer · hemophagocytic syndrome · hepatocellular carcinoma · infectious disease with sepsis · inflammatory disease · intermediate uveitis · ischemic disease · liver cancer · lymphoma · melanoma · myelin oligodendrocyte glycoprotein antibody-associated disease · nasopharyngeal carcinoma · obesity disorder · osteoarthritis, hand · ovarian cancer · pancreatic adenocarcinoma · panuveitis · peritoneal neoplasm · pleural neoplasm · posterior uveitis · prostate adenocarcinoma · pulmonary arterial hypertension · renal pelvis urothelial carcinoma · respiratory tract infectious disorder · rheumatoid arthritis-associated interstitial lung disease · schizoaffective disorder · Schnitzler syndrome · scleroderma · Sjogren syndrome · skin squamous cell carcinoma · soft tissue sarcoma · squamous cell carcinoma · systemic lupus erythematosus · transplant rejection · triple-negative breast carcinoma · type 1 diabetes mellitus · ureter cancer · urinary bladder cancer · urinary bladder carcinoma · urothelial carcinoma · acute myocardial infarction · amyotrophic lateral sclerosis · autoinflammatory syndrome · cardiac arrest · cardiogenic shock · chronic pancreatitis · Cogan syndrome · Cryoglobulinemic vasculitis · cutaneous polyarteritis nodosa · febrile infection-related epilepsy syndrome · HIV infectious disease · immunoglobulin A vasculitis · new-onset refractory status epilepticus · pneumonitis · primary bacterial infectious disease · primary central nervous system vasculitis · respiratory failure · type 2 diabetes mellitus
Investigated by
Hoffmann-La Roche · Chugai Pharmaceutical · Assistance Publique - Hôpitaux de Paris · Genentech, Inc. · National Cancer Institute (NCI) · Roche Pharma AG
+251 more · Insel Gruppe AG, University Hospital Bern · Massachusetts General Hospital · National Institute of Allergy and Infectious Diseases (NIAID) · Peking Union Medical College Hospital · URC-CIC Paris Descartes Necker Cochin · Centre Hospitalier Universitaire Dijon · Herlev Hospital · Medical College of Wisconsin · Oslo University Hospital · Roche Chugai · University of Chicago · Beijing VDJBio Co., LTD. · Brigham and Women's Hospital · Capital Medical University · Celgene Corporation · Chugai Pharma Taiwan · Columbia University · Emory University · Gilead Sciences · JW Pharmaceutical · M.D. Anderson Cancer Center · Medical University of Vienna · Memorial Sloan Kettering Cancer Center · NYU Langone Health · Nantes University Hospital · National Institutes of Health (NIH) · Norwegian University of Science and Technology · PPD Development, LP · Regeneron Pharmaceuticals · South-Eastern Norway Regional Health Authority · St. Olavs Hospital · Tang-Du Hospital · Tel-Aviv Sourasky Medical Center · Tianjin Medical University General Hospital · University Hospital, Brest · University Hospital, Strasbourg, France · University of Michigan Rogel Cancer Center · University of Nebraska · University of Oslo · Washington University School of Medicine · Weill Medical College of Cornell University · Abderrahmane Mami Hospital · Abramson Cancer Center at Penn Medicine · Academic Medical Center - University of Amsterdam · Adagene Inc · Affiliated Hospital of Nantong University · Alain Algazi · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · American Head and Neck Society · Amsterdam Rheumatology and Immunology Center · Arcus Biosciences, Inc. · Assaf-Harofeh Medical Center · Assistance Publique Hopitaux De Marseille · Assiut University · Australian and New Zealand Intensive Care Research Centre · Azienda Ospedaliera "Sant'Andrea" · Azienda Ospedaliera Ospedali Riuniti Marche Nord · Azienda Ospedaliero, Universitaria Pisana · Azienda USL Reggio Emilia - IRCCS · Beneficência Portuguesa de São Paulo · Berry Consultants · Bio-Thera Solutions · Biogen · Biogipuzkoa Health Research Institute · Bnai Zion Medical Center · Boston Medical Center · Brazilian Clinical Research Institute · Brazilian Research In Intensive Care Network · Breast Cancer Research Foundation · Brian Miller · Bristol-Myers Squibb · Cedars-Sinai Medical Center · Central People's Hospital of Zhanjiang · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts · all 257 on the full record

Regulatory milestones approvals, filings & regulatory actions · 18 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (16) US (FDA) ACTEMRA — 2011-01-04 – 2025-08-08 fda.gov ↗
Approved US (FDA) ACTEMRA — 2010-01-08 fda.gov ↗
Approved EU (EMA) RoActemra — 2009-01-16 europa.eu ↗

Trials 331 · started per year

today
EU approved 2009
US approved 2010
1
1
1
6
10
2
3
7
18
19
20
21
22
16
9
10
17
16
9
53
11
9
11
11
13
14
1
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT03970226 Sep 2019 → May 2024 overdue adamantinous craniopharyngioma University of Colorado, Denver Active not recruiting No outcome recorded
Phase 0 NCT02447055 Dec 2015 → Jun 2016 plasma cell myeloma Washington University School of Medicine Withdrawn No outcome recorded
Phase 129 trials
Phase 1 NCT07708038 Sep 2027 → Mar 2030 expected calciphylaxis Boston Medical Center Not yet recruiting No outcome recorded
Phase 1 NCT07392814 Mar 2026 → Jul 2028 expected acute myeloid leukemia Nantes University Hospital Not yet recruiting No outcome recorded
Phase 1 NCT06863480 Mar 2026 → Jul 2028 expected acquired aneurysmal subarachnoid hemorrhage, brain ischemia University of Florida Recruiting No outcome recorded
Phase 1 NCT06016179 Jan 2024 → Jan 2026 overdue peritoneal neoplasm, pleural neoplasm Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) Recruiting No outcome recorded
Phase 1 NCT06262477 Jan → Sep 2024 — Biogen Completed No outcome recorded
Phase 1 NCT05968508 Aug 2023 → Oct 2024 — Bio-Thera Solutions Completed No outcome recorded
Phase 1 NCT04616248 Jan 2023 → Jan 2027 expected basal cell carcinoma, bone sarcoma, breast carcinoma, cutaneous neuroendocrine carcinoma +3 University of Southern California Active not recruiting No outcome recorded
Phase 1 NCT05391750 Oct 2022 → Feb 2027 expected plasma cell myeloma Emory University Active not recruiting No outcome recorded
Phase 1 NCT05164133 Jun 2022 → Mar 2024 COVID-19 Hoffmann-La Roche Completed No outcome recorded
Phase 1 NCT04885829 May 2021 → May 2023 rheumatoid arthritis, temporal arteritis Syneos Health Completed No outcome recorded
Phase 1/219 trials
Phase 1/2 NCT07595900 Jun 2026 → Oct 2028 expected granulomatous mastitis Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting No outcome recorded
Phase 1/2 NCT04691817 Jul 2023 → Dec 2026 expected non-small cell lung carcinoma Abramson Cancer Center at Penn Medicine Recruiting No outcome recorded
Phase 1/2 NCT04842981 May 2021 → Sep 2022 rheumatoid arthritis University of Southern Denmark Terminated No outcome recorded
Phase 1/2 NCT04524871 Nov 2020 → Jul 2027 expected liver cancer Hoffmann-La Roche Recruiting No outcome recorded
Phase 1/2 NCT03867617 Aug 2019 → Jun 2024 overdue — Thomas Wekerle Active not recruiting No outcome recorded
Phase 1/2 NCT03869190 Jun 2019 → Oct 2025 urinary bladder cancer, urothelial carcinoma Hoffmann-La Roche Completed No outcome recorded
Phase 1/2 NCT03745586 Dec 2018 → Nov 2020 temporal arteritis Insel Gruppe AG, University Hospital Bern Completed No outcome recorded
Phase 1/2 NCT03533101 May 2018 → May 2019 cytokine release syndrome, disease related to hematopoietic stem cell transplant Hospital Universitario Dr. Jose E. Gonzalez Completed No outcome recorded
Phase 1/2 NCT03564340 May 2018 → May 2027 expected endometrial cancer, fallopian tube cancer, malignant ovarian serous tumor, primary peritoneal carcinoma Regeneron Pharmaceuticals Recruiting No outcome recorded
Phase 1/2 NCT03424005 Mar 2018 → Sep 2030 expected breast cancer Hoffmann-La Roche Recruiting No outcome recorded
Phase 290 trials
Phase 2 NCT03787290 Dec 2026 → Dec 2028 major depressive disorder Massachusetts General Hospital Suspended No outcome recorded
Phase 2 NCT07589634 Jul 2026 → Dec 2027 expected plasma cell myeloma Janssen Research & Development, LLC Recruiting No outcome recorded
Phase 2 NCT07052058 Jul 2026 → Jul 2028 expected major depressive disorder Hospital de Clinicas de Porto Alegre Not yet recruiting No outcome recorded
Phase 2 NCT06381661 May 2026 → Jun 2028 expected infectious disease with sepsis Assistance Publique - Hôpitaux de Paris Not yet recruiting No outcome recorded
Phase 2 NCT07254637 Apr → Oct 2026 expected chondrocalcinosis Assistance Publique - Hôpitaux de Paris Not yet recruiting No outcome recorded
Phase 2 NCT07493317 Mar 2026 → Feb 2031 expected major depressive disorder Icahn School of Medicine at Mount Sinai Recruiting No outcome recorded
Phase 2 NCT07138898 Dec 2025 → Jan 2028 expected rheumatic disorder NYU Langone Health Recruiting No outcome recorded
Phase 2 NCT07108387 Dec 2025 → Jun 2027 expected temporal arteritis National Institute of Allergy and Infectious Diseases (NIAID) Recruiting No outcome recorded
Phase 2 NCT07334379 Oct 2025 → Oct 2026 expected acute respiratory failure Lorenzo delSorbo Recruiting No outcome recorded
Phase 2 NCT06941376 Aug 2025 → Jul 2027 expected relapsing polychondritis University of Pennsylvania Recruiting No outcome recorded
Phase 2/38 trials
Phase 2/3 NCT06452537 Jul 2024 → Jan 2026 overdue myelin oligodendrocyte glycoprotein antibody-associated disease Tianjin Medical University General Hospital Active not recruiting No outcome recorded
Phase 2/3 NCT06238024 Feb → Jun 2024 ischemic stroke Suzhou Municipal Hospital of Anhui Province Completed No outcome recorded
Phase 2/3 NCT05716035 Apr 2023 → Jul 2024 generalized myasthenia gravis Tang-Du Hospital Unknown No outcome recorded
Phase 2/3 NCT05963048 Dec 2021 → Dec 2022 interstitial lung disease, scleroderma Assiut University Completed No outcome recorded
Phase 2/3 NCT04349410 Apr → Sep 2020 COVID-19 The Camelot Foundation Completed No outcome recorded
Phase 2/3 NCT03353259 Nov 2017 → Feb 2021 — Oslo University Hospital Terminated No outcome recorded
Phase 2/3 NCT03350633 Nov 2017 → Sep 2019 neuromyelitis optica Tianjin Medical University General Hospital Completed No outcome recorded
Phase 2/3 NCT01782235 Jul 2013 → Jul 2018 Sjogren syndrome University Hospital, Strasbourg, France Completed No outcome recorded
Phase 3118 trials
Phase 3 NCT07335562 Aug 2026 → Nov 2028 expected systemic sclerosis Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Recruiting No outcome recorded
Phase 3 NCT07509645 Apr 2026 → Apr 2027 expected ischemic stroke Capital Medical University Recruiting No outcome recorded
Phase 3 NCT07263776 Dec 2025 → Sep 2026 expected ischemic stroke Capital Medical University Active not recruiting No outcome recorded
Phase 3 NCT06447701 Oct → Dec 2025 overdue cerebral atherosclerosis, cerebral infarction, ischemic disease Zhujiang Hospital Not yet recruiting No outcome recorded
Phase 3 NCT06818266 Aug 2025 → Apr 2027 expected acute chest syndrome, sickle cell disease Assistance Publique - Hôpitaux de Paris Recruiting No outcome recorded
Phase 3 NCT06297096 Jul 2025 → Dec 2027 expected interstitial lung disease, systemic sclerosis National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland Recruiting No outcome recorded
Phase 3 NCT04871191 Jun 2025 → Oct 2028 expected granulomatosis with polyangiitis Assistance Publique - Hôpitaux de Paris Recruiting No outcome recorded
Phase 3 NCT06726096 Apr 2025 → Apr 2026 overdue rheumatoid arthritis Beijing VDJBio Co., LTD. Enrolling by invitation No outcome recorded
Phase 3 NCT06037460 May 2024 → Dec 2027 expected temporal arteritis Centre Hospitalier Universitaire Dijon Active not recruiting No outcome recorded
Phase 3 NCT05346666 Jun 2022 → Sep 2023 epilepsy Damanhour University Unknown No outcome recorded
Show all 118 trials opens the full record — a long page
Phase 446 trials
Phase 4 NCT07609940 Jul 2026 → Oct 2027 expected refractory plasma cell neoplasm Regeneron Pharmaceuticals Not yet recruiting No outcome recorded
Phase 4 NCT07643038 Jul 2026 → Jul 2029 expected rheumatoid arthritis-associated interstitial lung disease Chinese SLE Treatment And Research Group Not yet recruiting No outcome recorded
Phase 4 NCT07582185 Jun → Sep 2026 expected rheumatoid arthritis Centre Hospitalier Universitaire de Nice Not yet recruiting No outcome recorded
Phase 4 NCT06927375 Dec 2024 → Nov 2025 overdue disease of orbital part of eye adnexa Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University Recruiting No outcome recorded
Phase 4 NCT06251076 Nov 2024 → Jun 2026 overdue plasma cell myeloma, refractory malignant neoplasm University Health Network, Toronto Recruiting No outcome recorded
Phase 4 NCT06498089 Jun 2024 → Jun 2026 overdue Takayasu arteritis Shanghai Zhongshan Hospital Recruiting No outcome recorded
Phase 4 NCT05855122 Apr 2023 → Aug 2024 plasma cell myeloma The First Affiliated Hospital of Soochow University Unknown No outcome recorded
Phase 4 NCT05604859 Aug 2022 → Dec 2023 — Qin Ning Unknown No outcome recorded
Phase 4 NCT04762784 Jul 2020 → Feb 2023 — Peking Union Medical College Hospital Unknown No outcome recorded
Phase 4 NCT04730323 May → Jun 2020 COVID-19 FMH College of Medicine and Dentistry Completed No outcome recorded
Phase not applicable18 trials
— NCT07377058 Nov 2025 → Oct 2026 expected dermatomyositis Peking Union Medical College Hospital Recruiting No outcome recorded
— NCT07491913 Jun 2025 → Dec 2027 expected Takayasu arteritis Marmara University Recruiting No outcome recorded
— NCT07006532 Jan 2025 → Jan 2027 expected transplant rejection Shahid Beheshti University of Medical Sciences Recruiting No outcome recorded
— NCT05305066 Feb 2023 → Dec 2028 expected rheumatoid arthritis Marie Hudson, MD Recruiting No outcome recorded
— NCT05349149 Apr → Oct 2022 — Helga Ellingsgaard Completed No outcome recorded
— NCT05082714 Oct 2021 → Jun 2022 COVID-19 University Hospital of Patras Completed No outcome recorded
— NCT06442709 Aug 2021 → Jul 2024 nasopharyngeal carcinoma Affiliated Hospital of Nantong University Unknown No outcome recorded
— NCT04690920 Jul → Dec 2020 COVID-19 University of Lahore Completed No outcome recorded
— NCT04492501 Apr → Jul 2020 COVID-19, acute respiratory distress syndrome, cytokine release syndrome UNICEF Completed No outcome recorded
— NCT04519385 Mar → Jul 2020 viral pneumonia South Valley University Completed No outcome recorded
Phase not stated1 trial
— NCT00862758 Feb 2009 → Oct 2010 polyarticular juvenile idiopathic arthritis University of Oklahoma No longer available No outcome recorded
Also used as a comparator or background therapy in 132 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 143 trials
Phase 1 NCT07573332 Background Sep 2026 → Aug 2030 expected neuromyelitis optica spectrum disorder with anti-AQP4 antibodies University of Texas Southwestern Medical Center Not yet recruiting No outcome recorded
Phase 1 NCT07629583 Background Jul 2026 → Mar 2030 expected systemic lupus erythematosus Genentech, Inc. Not yet recruiting No outcome recorded
Phase 1 NCT07594067 Background Jul 2026 → Jul 2042 expected cholangiocarcinoma, colorectal cancer, non-small cell lung carcinoma, pancreatic adenocarcinoma University of Pennsylvania Recruiting No outcome recorded
Phase 1 NCT07115745 Background Sep 2025 → Mar 2029 expected — Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Recruiting No outcome recorded
Phase 1 NCT06934044 Background May 2025 → Nov 2028 expected plasma cell myeloma Hoffmann-La Roche Recruiting No outcome recorded
Phase 1/220 trials
Phase 1/2 NCT07227597 Background Jan 2026 → Nov 2030 expected small cell lung carcinoma Merck Sharp & Dohme LLC Recruiting No outcome recorded
Phase 1/2 NCT07113743 Background Sep 2025 → Sep 2028 expected granulomatous disease, chronic, X-linked National Institute of Allergy and Infectious Diseases (NIAID) Enrolling by invitation No outcome recorded
Phase 1/2 NCT05583617 Background Nov 2023 → Jul 2028 expected plasma cell myeloma Hoffmann-La Roche Recruiting No outcome recorded
Phase 1/2 NCT05533775 Background Nov 2022 → Nov 2029 expected B-cell non-Hodgkin lymphoma Hoffmann-La Roche Recruiting No outcome recorded
Phase 1/2 NCT05535244 Background Oct 2022 → Feb 2027 expected plasma cell myeloma Hoffmann-La Roche Active not recruiting No outcome recorded
Phase 220 trials
Phase 2 NCT07709000 Background Aug 2026 → Nov 2033 expected chronic lymphocytic leukemia/small lymphocytic lymphoma Merck Sharp & Dohme LLC Not yet recruiting No outcome recorded
Phase 2 NCT07637578 Background Aug 2026 → Oct 2029 expected plasma cell myeloma SCRI Development Innovations, LLC Not yet recruiting No outcome recorded
Phase 2 NCT06426160 Comparator May 2024 → Jun 2026 chronic pancreatitis Soren Schou Olesen Unknown No outcome recorded
Phase 2 NCT06043674 Background Jan 2024 → Jan 2028 expected B-cell chronic lymphocytic leukemia, Richter transformation Christine Ryan Recruiting No outcome recorded
Phase 2 NCT05833763 Background Oct 2023 → Apr 2032 expected mantle cell lymphoma Australasian Leukaemia and Lymphoma Group Recruiting No outcome recorded
Phase 2/32 trials
Phase 2/3 NCT07570173 Background May 2026 → Oct 2033 expected B-cell acute lymphoblastic leukemia Merck Sharp & Dohme LLC Recruiting No outcome recorded
Phase 2/3 NCT04347031 Background Apr → Nov 2020 respiratory failure, viral pneumonia Burnasyan Federal Medical Biophysical Center Completed No outcome recorded
Phase 321 trials
Phase 3 NCT07281027 Comparator Jul 2026 → Mar 2030 expected febrile infection-related epilepsy syndrome, new-onset refractory status epilepticus Yale University Not yet recruiting No outcome recorded
Phase 3 NCT06654882 Comparator Jan → Dec 2026 expected polyarticular juvenile idiopathic arthritis Duke University Recruiting No outcome recorded
Phase 3 NCT06084936 Background Oct 2023 → Aug 2027 expected lymphoma Hoffmann-La Roche Recruiting No outcome recorded
Phase 3 NCT05609630 Comparator Oct 2023 → Jun 2029 expected systemic-onset juvenile idiopathic arthritis AbbVie Recruiting No outcome recorded
Phase 3 NCT06475508 Comparator Feb 2023 → Jan 2024 rheumatoid arthritis AO GENERIUM Completed No outcome recorded
Phase 416 trials
Phase 4 NCT06624436 Comparator Oct 2024 → Sep 2025 overdue infectious disease with sepsis, primary bacterial infectious disease Radboud University Medical Center Recruiting No outcome recorded
Phase 4 NCT05730777 Background Feb → Jul 2023 chemotherapy-induced toxicity Peking University Third Hospital Unknown No outcome recorded
Phase 4 NCT05133635 Comparator Feb → Apr 2021 COVID-19, cytokine release syndrome Marmara University Withdrawn No outcome recorded
Phase 4 NCT04779047 Comparator Oct 2020 → Mar 2021 COVID-19, pneumonia October 6 University Unknown No outcome recorded
Phase 4 NCT03895879 Comparator Mar 2020 → Dec 2024 rheumatoid arthritis Reade Rheumatology Research Institute Unknown No outcome recorded
Phase not applicable10 trials
— NCT06721910 Comparator Jan → Sep 2025 — University Hospital, Basel, Switzerland Completed No outcome recorded
— NCT04687540 Comparator Apr → Aug 2021 obesity disorder Rigshospitalet, Denmark Completed No outcome recorded
— NCT04616235 Comparator Mar → Oct 2021 — Rigshospitalet, Denmark Completed No outcome recorded
— NCT05279391 Comparator Oct 2020 → Nov 2021 respiratory failure Democritus University of Thrace Unknown No outcome recorded
— NCT04380818 Background Jun 2020 → Sep 2021 viral pneumonia Grupo de Investigación Clínica en Oncología Radioterapia Unknown No outcome recorded

Press releases naming this drug 22 releases

DateIssuerRelease
2026-06-10 Organon and Co Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19 organon.com ↗
2025-04-01 Organon and Co Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S. organon.com ↗
2022-12-21 Roche Global Development FDA approves Roche’s Actemra for the treatment of COVID-19 in hospitalised adults roche.com ↗
2022-04-04 Roche Global Development U.S. FDA grants priority review to Roche’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults roche.com ↗
2022-02-11 Roche Global Development WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19 roche.com ↗
2021-12-07 Roche Global Development Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19 roche.com ↗
2021-12-06 Roche Global Development CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19 roche.com ↗
2021-06-25 Roche Global Development Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children roche.com ↗
2021-04-15 Novartis Pharmaceuticals Novartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra® novartis.com ↗
2021-03-11 Roche Global Development Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia roche.com ↗
2021-03-05 Roche Global Development Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition roche.com ↗
2020-09-18 Roche Global Development Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia roche.com ↗

Evidence & citations 21 cited values

Every value below carries the sentence it was read from. 490 sources stand behind the page.

FieldValueCited text
Known as Tocilizumab “Tocilizumab (Ro-Actemra®) will be administered every 4 weeks at a dose of 8 mg/kg BW (maximum dose of 800 mg); The employed dosage will be calculated using manufacturer...” NCT01638715 ↗
448

“Recommended rescue medications include tocilizumab for treatment of cytokine release syndrome (CRS); dexamethasone, acetaminophen, and diphenhydramine for CRS/infusion-related...” NCT07227597 ↗

“This clinical trial is testing a drug called Tocilizumab (a monoclonal antibody) as a first line therapy for subjects with steroid-refractory acute graft versus host disease...” NCT01757197 ↗

“This study compared the pharmacokinetics (PK), safety, and immunogenicity of the Tocilizumab biosimilar, BAT1806 SC (Tocilizumab biosimilar, Subcutaneous Injection), with...” PMID 41069221 ↗ Oct 2025

“Tocilizumab, an interleukin 6 receptor (IL-6R) antagonist monoclonal antibody, has shown efficacy in patients with coronavirus disease 2019 (COVID-19) pneumonia, but the...” PMID 35024375 ↗ Dec 2021

“Dose tapering of tocilizumab followed by complete treatment discontinuation after a 3-month tapering period in patients with Takayasu arteritis in sustained clinical and...” NCT07491913 ↗

“Switching to a non-TNFi-biologic (choice from non-TNFi-biologics; currently available are rituximab, abatacept, tocilizumab, or sarilumab) in people with active RA despite...” NCT04692493 ↗

“Tocilizumab is a humanized recombinant IgG1 monoclonal antibody to human interleukin-6 (IL-6) receptor, produced in Chinese hamster ovary cells by recombinant DNA technology.” NCT05002517 ↗

“Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.” PMID 20112381 ↗ Feb 2010

“Using Tocilizumab, an Humanized Monoclonal Antibody Against the Interleukin - 6 Receptor in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy” NCT04652258 ↗

“Currently, there are two available drugs based on human monoclonal antibodies against IL-6 receptor, tocilizumab (RoActemra, Roche) and sarilumab (Kevzara, Sanofi).” NCT04322773 ↗

“tocilizumab (if weight \<100 kg: 162 mg SC every other week, followed by an increase to weekly based on clinical response; if weight ≥100 kg: 162 mg SC weekly)” NCT05305066 ↗

“bDMARDS (etanercept, adalimumab, infliximab, certolizumab, golimumab, tocilizumab, abatacept) will be discontinued after baseline visit in all participants” NCT01602302 ↗

“all patients will receive an infusion of tocilizumab at 8 mg/kg body weight on day 0 before CAR-T cells infusion” NCT04499573 ↗

“Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week.” NCT01491815 ↗

“Tocilizumab Dose: 8 mg / kg (maximum dose of 800 mg) IV, maximum 3 doses 8 to 12 hours apart” NCT04536363 ↗

“Tocilizumab will be administered as needed to manage cytokine release syndrome (CRS) events” NCT04712097 ↗

“TOCILIZUMAB administered at standardized, fixed-interval doses versus weight-based dosing” NCT07582185 ↗

“Patients are treated with infusions of Tocilizumab (TCZ) for 3 months.” NCT01713842 ↗

“Tocilizumab 400 mg (weight \<75Kgs) or 600 mg (weight ≥ 75 Kg)” NCT04374539 ↗

“preemptive IL-6 receptor (IL-6R) blockade using tocilizumab” NCT04496674 ↗

“Methotrexate or leflunomide + tocilizumab or” NCT02714634 ↗

“Tocilizumab 20 MG/ML Intravenous (one dose)” NCT04435717 ↗

“* abatacept * tocilizumab * rituximab” NCT04000698 ↗

“Tocilizumab Injection 8 mg/kg” NCT06726096 ↗

“Tocilizumab Injection8mg/kg” NCT05957107 ↗

“Tocilizumab (RoActemra®)” NCT02779114 ↗

“Drug: tocilizumab” NCT02049437 ↗

“Tocilizumab vial” NCT05022927 ↗

NCT02324257 ↗

NCT03202368 ↗

NCT02901496 ↗

NCT02010216 ↗

NCT07377058 ↗

NCT02011334 ↗

NCT00996203 ↗

NCT00951275 ↗

NCT07493317 ↗

NCT01717170 ↗

NCT00996606 ↗

NCT03448042 ↗

NCT05391750 ↗

NCT01399697 ↗

NCT01610791 ↗

NCT02293837 ↗

NCT07254637 ↗

NCT04492501 ↗

NCT02108600 ↗

NCT05091424 ↗

NCT01396317 ↗

NCT04762784 ↗

NCT07138898 ↗

NCT04888221 ↗

NCT03446209 ↗

NCT05090410 ↗

NCT01283971 ↗

NCT02336048 ↗

NCT01000441 ↗

NCT02007239 ↗

NCT04476979 ↗

NCT01163747 ↗

NCT06251076 ↗

NCT03353259 ↗

NCT04479358 ↗

NCT01715831 ↗

NCT04730323 ↗

NCT03999749 ↗

NCT01693653 ↗

NCT05364424 ↗

NCT00810199 ↗

NCT02874573 ↗

NCT00810277 ↗

NCT04729959 ↗

NCT03522012 ↗

NCT02348216 ↗

NCT07509645 ↗

NCT01002781 ↗

NCT05129280 ↗

NCT07006532 ↗

NCT02057770 ↗

NCT06087731 ↗

NCT05133635 ↗

NCT04885829 ↗

NCT02419937 ↗

NCT03895879 ↗

NCT03507348 ↗

NCT06084936 ↗

NCT06654882 ↗

NCT04239196 ↗

NCT06238024 ↗

NCT02031471 ↗

NCT02034474 ↗

NCT05082714 ↗

NCT02385110 ↗

NCT01073826 ↗

NCT04657302 ↗

NCT07708038 ↗

NCT01730456 ↗

NCT03227419 ↗

NCT01717859 ↗

NCT02840175 ↗

NCT07709000 ↗

NCT01696929 ↗

NCT00535782 ↗

NCT05874505 ↗

NCT00862758 ↗

NCT03708224 ↗

NCT02676947 ↗

NCT01007435 ↗

NCT00721123 ↗

NCT04246086 ↗

NCT04616235 ↗

NCT05869955 ↗

NCT02097524 ↗

NCT03677154 ↗

NCT02929251 ↗

NCT03677141 ↗

NCT06498089 ↗

NCT02573012 ↗

NCT01603355 ↗

NCT05646836 ↗

NCT04007029 ↗

NCT07263776 ↗

NCT06927375 ↗

NCT01450137 ↗

NCT05155345 ↗

NCT04616248 ↗

NCT04693026 ↗

NCT03644667 ↗

NCT01010503 ↗

NCT04423042 ↗

NCT04940299 ↗

NCT00750880 ↗

NCT00720798 ↗

NCT00988221 ↗

NCT01441063 ↗

NCT02682823 ↗

NCT02165345 ↗

NCT01475162 ↗

NCT01149057 ↗

NCT02735707 ↗

NCT01258712 ↗

NCT05350592 ↗

NCT05640271 ↗

NCT02511067 ↗

NCT05716035 ↗

NCT02001987 ↗

NCT01532869 ↗

NCT06818266 ↗

NCT05164133 ↗

NCT04258150 ↗

NCT06381661 ↗

NCT04412772 ↗

NCT01587989 ↗

NCT05349149 ↗

NCT01089023 ↗

NCT04876534 ↗

NCT00773461 ↗

NCT03601611 ↗

NCT03533283 ↗

NCT04412291 ↗

NCT00365001 ↗

NCT03193190 ↗

NCT04424056 ↗

NCT03350633 ↗

NCT01256736 ↗

NCT05168475 ↗

NCT03892785 ↗

NCT05346666 ↗

NCT01791842 ↗

NCT05169515 ↗

NCT00531817 ↗

NCT05171647 ↗

NCT00848120 ↗

NCT01791153 ↗

NCT05070247 ↗

NCT03215407 ↗

NCT01673919 ↗

NCT01878318 ↗

NCT04691817 ↗

NCT02453256 ↗

NCT07052058 ↗

NCT01183598 ↗

NCT02353780 ↗

NCT03970226 ↗

NCT01468077 ↗

NCT01418989 ↗

NCT04600141 ↗

NCT05181397 ↗

NCT06624436 ↗

NCT06043674 ↗

NCT06624085 ↗

NCT03671018 ↗

NCT02404558 ↗

NCT07392814 ↗

NCT04690920 ↗

NCT01254331 ↗

NCT02767557 ↗

NCT06037460 ↗

NCT00109408 ↗

NCT00891020 ↗

NCT04519385 ↗

NCT03434730 ↗

NCT01491074 ↗

NCT01297699 ↗

NCT00144664 ↗

NCT04409262 ↗

NCT00144651 ↗

NCT06033196 ↗

NCT01782235 ↗

NCT02043548 ↗

NCT03275103 ↗

NCT04408638 ↗

NCT06372574 ↗

NCT01251120 ↗

NCT04871854 ↗

NCT01734382 ↗

NCT05619744 ↗

NCT04381936 ↗

NCT04871191 ↗

NCT01637532 ↗

NCT03726749 ↗

NCT01941095 ↗

NCT00144625 ↗

NCT00144612 ↗

NCT00642460 ↗

NCT00144599 ↗

NCT03737708 ↗

NCT03533101 ↗

NCT01941940 ↗

NCT00144586 ↗

NCT00144573 ↗

NCT00144560 ↗

NCT05333302 ↗

NCT00144547 ↗

NCT07281027 ↗

NCT06426160 ↗

NCT06934044 ↗

NCT01734993 ↗

NCT00144534 ↗

NCT00144521 ↗

NCT04088396 ↗

NCT01557374 ↗

NCT05855122 ↗

NCT03863015 ↗

NCT00144508 ↗

NCT05067348 ↗

NCT07570173 ↗

NCT07573332 ↗

NCT00868751 ↗

NCT05207670 ↗

NCT02837146 ↗

NCT00106574 ↗

NCT05846789 ↗

NCT00106548 ↗

NCT00106535 ↗

NCT00106522 ↗

NCT03075696 ↗

NCT04380818 ↗

NCT05609630 ↗

NCT05604859 ↗

NCT06430736 ↗

NCT06016179 ↗

NCT03967691 ↗

NCT05845723 ↗

NCT01195272 ↗

NCT07115745 ↗

NCT01194414 ↗

NCT04377750 ↗

NCT04377659 ↗

NCT03004703 ↗

NCT04377503 ↗

NCT01353859 ↗

NCT01668966 ↗

NCT03781310 ↗

NCT05219513 ↗

NCT04688021 ↗

NCT04300686 ↗

NCT01855789 ↗

NCT02046603 ↗

NCT05769959 ↗

NCT00887341 ↗

NCT01245452 ↗

NCT01245439 ↗

NCT04082910 ↗

NCT03866239 ↗

NCT02046616 ↗

NCT01772316 ↗

NCT04524871 ↗

NCT04375228 ↗

NCT03923738 ↗

NCT07113743 ↗

NCT03046381 ↗

NCT05925140 ↗

NCT02843789 ↗

NCT04580121 ↗

NCT01034137 ↗

NCT01034397 ↗

NCT03564340 ↗

NCT03588936 ↗

NCT00977106 ↗

NCT06297096 ↗

NCT04687540 ↗

NCT07335562 ↗

NCT01910038 ↗

NCT03867617 ↗

NCT07589634 ↗

NCT04403685 ↗

NCT04310228 ↗

NCT04842981 ↗

NCT05583617 ↗

NCT02765074 ↗

NCT01347983 ↗

NCT01119859 ↗

NCT01995201 ↗

NCT05833763 ↗

NCT05232396 ↗

NCT05927571 ↗

NCT01768572 ↗

NCT01120366 ↗

NCT04372186 ↗

NCT07334379 ↗

NCT01242488 ↗

NCT01667471 ↗

NCT03135171 ↗

NCT03869190 ↗

NCT06442709 ↗

NCT02101333 ↗

NCT03745586 ↗

NCT04313608 ↗

NCT01455701 ↗

NCT04370834 ↗

NCT07594067 ↗

NCT04315480 ↗

NCT03699631 ↗

NCT07595900 ↗

NCT04317092 ↗

NCT03263715 ↗

NCT04077723 ↗

NCT00754559 ↗

NCT00883753 ↗

NCT00754572 ↗

NCT01649804 ↗

NCT04564001 ↗

NCT01209702 ↗

NCT01951170 ↗

NCT03554161 ↗

NCT01211834 ↗

NCT05233397 ↗

NCT01063062 ↗

NCT04445272 ↗

NCT05835986 ↗

NCT01904292 ↗

NCT00845832 ↗

NCT03787290 ↗

NCT01904279 ↗

NCT04560205 ↗

NCT01041248 ↗

NCT02477059 ↗

NCT04910568 ↗

NCT07108387 ↗

NCT02997956 ↗

NCT04320615 ↗

NCT03539484 ↗

NCT04551352 ↗

NCT03062579 ↗

NCT06447701 ↗

NCT02087696 ↗

NCT02469896 ↗

NCT02447055 ↗

NCT04363853 ↗

NCT01727986 ↗

NCT04561986 ↗

NCT04554771 ↗

NCT02287922 ↗

NCT01332994 ↗

NCT06941376 ↗

NCT02660528 ↗

NCT01209689 ↗

NCT03155347 ↗

NCT04321993 ↗

NCT02908217 ↗

NCT01594424 ↗

NCT01331837 ↗

NCT01987479 ↗

NCT01991990 ↗

NCT01044498 ↗

NCT04361552 ↗

NCT04361032 ↗

NCT01655381 ↗

NCT03337698 ↗

NCT01214733 ↗

NCT01665430 ↗

NCT07609940 ↗

NCT02174263 ↗

NCT07643038 ↗

NCT02659150 ↗

NCT00380601 ↗

NCT06721910 ↗

NCT04547062 ↗

NCT01575769 ↗

NCT04394182 ↗

NCT04330638 ↗

NCT06452537 ↗

NCT04356937 ↗

NCT01326962 ↗

NCT04779047 ↗

NCT04070781 ↗

NCT04331795 ↗

NCT01219933 ↗

NCT07637578 ↗

NCT05535244 ↗

NCT04331808 ↗

NCT04332094 ↗

NCT01235507 ↗

NCT05533775 ↗

NCT05279391 ↗

NCT00965653 ↗

NCT04335071 ↗

NCT04335305 ↗

NCT03100253 ↗

NCT05972135 ↗

NCT01988012 ↗

NCT04338685 ↗

NCT04779957 ↗

NCT01232569 ↗

NCT03244709 ↗

NCT03467373 ↗

NCT01661140 ↗

NCT03467256 ↗

NCT01727206 ↗

NCT01664598 ↗

NCT01662063 ↗

NCT04349410 ↗

NCT04339712 ↗

NCT04395222 ↗

NCT04157010 ↗

NCT04347031 ↗

NCT03424005 ↗

NCT02906371 ↗

NCT04066114 ↗

NCT03821246 ↗

NCT04345445 ↗

NCT02206035 ↗

NCT01104480 ↗

NCT04346355 ↗

NCT07629583 ↗

NCT03301883 ↗

NCT04980222 ↗
Known as Actemra “This multicenter, open-label, single arm study will assess the safety and efficacy of RoActemra/Actemra (tocilizumab) in combination with methotrexate in patients with active...” NCT01353859 ↗
66

“This long-term, interventional, open-label extension study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients from Poland and Russia with...” NCT01575769 ↗

“This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who...” NCT01667471 ↗

“This multicenter, randomized, double-blind, placebo-controlled, two-arm, parallel-group study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in...” NCT01532869 ↗

“CT-P47, containing the active ingredient tocilizumab, is a recombinant humanized monoclonal antibody that is being developed as a similar biological medicinal product to...” NCT05489224 ↗

“In the experimental arm, patients will receive a single standard dose of Tocilizumab (Actemra®) 8 mg/kg b.w. intravenously infused over 1 hour in 250 ml NaCl 0.9%” NCT06430736 ↗

“This multicenter, open-label, single-arm extension study will evaluate the long-term safety of tocilizumab (RoActemra/Actemra) in participants with RA.” NCT01715831 ↗

“A Study of Administration of RoActemra/Actemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers” NCT01418989 ↗

“Subjects will receive 8mg/kg intravenous(IV) ACTEMRA® at Week 0,Week 4, Week 8, Week 12, Week 16, Week 20,Week 24” NCT06048224 ↗

“Participants will receive Tocilizumab (ACTEMRA®) at 4, 6, or 8 mg/kg IV dose escalation on days 1, 29 and 57.” NCT02997956 ↗

“after administration of Actemra (tocilizumab) in patients who have fever and other cytokine release symptoms” NCT04652258 ↗

“Tocilizumab (Actemra) is administered via intravenous infusion at a dose of 400 mg at Weeks 0, 4, and 8.” NCT06927375 ↗

“RoActemra/Actemra (tocilizumab) in combination with methotrexate versus RoActemra/Actemra monotherapy” NCT01587989 ↗

“RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis” NCT01673919 ↗

“A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis” NCT01245439 ↗

“A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis” NCT01214733 ↗

“Participants will receive one 30 min intravenous infusion of tocilizumab/Actemra® (Roche).” NCT05349149 ↗

“MSB11456, US-licensed Actemra® and EU-approved RoActemra® in Healthy Adult Subjects” NCT03282851 ↗

“A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis” NCT01209689 ↗

“Tocilizumab Prefilled Syringe [Actemra]. propofole, phenobarbital, midazolam” NCT05346666 ↗

“disclosed the off-label product use of tocilizumab (Actemra).” PMID 34612846 ↗ Mar 2022

“Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1” NCT04435717 ↗

“Biological: Tocilizumab (Actemra or RoActemra)” NCT01242488 ↗

“tocilizumab (Actemra) is safe and effective” NCT01603355 ↗

“Drug: tocilizumab [RoActemra/Actemra]” NCT00965653 ↗

“Drug: tocilizumab [RoActemra/Actemra]” NCT00754572 ↗

“tocilizumab [RoActemra/Actemra]” NCT01730456 ↗

“tocilizumab [RoActemra/Actemra]” NCT00848120 ↗

“tocilizumab [RoActemra/Actemra]” NCT01063062 ↗

“tocilizumab [RoActemra/Actemra]” NCT01183598 ↗

“tocilizumab (RoActemra/Actemra)” NCT01664598 ↗

“RoActemra/Actemra (tocilizumab)” NCT01326962 ↗

“tocilizumab [RoActemra/Actemra]” NCT00773461 ↗

“tocilizumab [RoActemra/Actemra]” NCT01991990 ↗

“tocilizumab [RoActemra/Actemra]” NCT01332994 ↗

“tocilizumab [RoActemra/Actemra]” NCT01149057 ↗

“tocilizumab [RoActemra/Actemra]” NCT01649804 ↗

“tocilizumab [RoActemra/Actemra]” NCT01034397 ↗

“tocilizumab [RoActemra/Actemra]” NCT00951275 ↗

“RoActemra/Actemra (tocilizumab)” NCT01995201 ↗

“tocilizumab [RoActemra/Actemra]” NCT00977106 ↗

“tocilizumab [RoActemra/Actemra]” NCT00891020 ↗

“tocilizumab [RoActemra/Actemra]” NCT01089023 ↗

“tocilizumab [RoActemra/Actemra]” NCT00365001 ↗

“tocilizumab [RoActemra/Actemra]” NCT01878318 ↗

“tocilizumab [RoActemra/Actemra]” NCT01251120 ↗

“tocilizumab [RoActemra/Actemra]” NCT00642460 ↗

“tocilizumab [RoActemra/Actemra]” NCT00106522 ↗

“tocilizumab [RoActemra/Actemra]” NCT01195272 ↗

“tocilizumab [RoActemra/Actemra]” NCT00109408 ↗

“tocilizumab [RoActemra/Actemra]” NCT01727986 ↗

“tocilizumab [RoActemra/Actemra]” NCT01235507 ↗

“tocilizumab [RoActemra/Actemra]” NCT00750880 ↗

“tocilizumab [RoActemra/Actemra]” NCT01219933 ↗

“tocilizumab [RoActemra/Actemra]” NCT01010503 ↗

“tocilizumab [RoActemra/Actemra]” NCT00810277 ↗

“tocilizumab [RoActemra/Actemra]” NCT01610791 ↗

“tocilizumab [RoActemra/Actemra]” NCT00996203 ↗

“tocilizumab [RoActemra/Actemra]” NCT00883753 ↗

“Tocilizumab (Actemra®)” NCT07334379 ↗

“Actemra” NCT05963048 ↗

NCT03830203 ↗

NCT06262477 ↗

NCT06048224 ↗

NCT06481202 ↗

NCT06475508 ↗

NCT03282851 ↗
Known as ActemraMR “The FDA recently approved a randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the safety and efficacy of TCZ (ActemraMR) added to standard care...” NCT04363853 ↗
Known as Actmera “study drug anti-IL6R (Tocilizumab (Actmera)) 8 mg/kg given IV during one hour once.” NCT04377750 ↗
Known as Atlizumab ClinicalTrials.gov intervention name — accepted as the source's own label NCT05730777 ↗
Known as humanized anti-IL6 receptor antibody “humanized anti-IL6 receptor antibody” NCT02101333 ↗
Known as MRA “Drug: MRA(Tocilizumab)” NCT00144599 ↗
12

“MRA (Tocilizumab)” NCT00144534 ↗

“MRA (Tocilizumab)” NCT00144508 ↗

“MRA(Tocilizumab)” NCT00144625 ↗

“MRA(Tocilizumab)” NCT00144651 ↗

“MRA(Tocilizumab)” NCT00144664 ↗

“MRA(Tocilizumab)” NCT00144612 ↗

“MRA(Tocilizumab)” NCT00144547 ↗

“MRA(Tocilizumab)” NCT00144586 ↗

“MRA(Tocilizumab)” NCT00144573 ↗

“MRA(Tocilizumab)” NCT00144560 ↗

“MRA(Tocilizumab)” NCT00144521 ↗

“MRA(Tocilizumab)” NCT00380601 ↗
Known as RO4877533 “Tocilizumab (TCZ, RO4877533)” NCT01044498 ↗
Known as RoAcemtra “Tocilizumab Infusion RoAcemtra (EU) or Actemra (Rest of the world)” NCT03446209 ↗
Known as RoActembra “Tocilizumab (RoActembra). Vials of 20 ml with 400 mg (20mg/ml) and 4ml with 80 mg (20mg/ml).” NCT04363853 ↗
Known as RoActemra “Tocilizumab (Ro-Actemra®) will be administered every 4 weeks at a dose of 8 mg/kg BW (maximum dose of 800 mg); The employed dosage will be calculated using manufacturer...” NCT01638715 ↗
64

“This multicenter, open-label, single arm study will assess the safety and efficacy of RoActemra/Actemra (tocilizumab) in combination with methotrexate in patients with active...” NCT01353859 ↗

“This long-term, interventional, open-label extension study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients from Poland and Russia with...” NCT01575769 ↗

“This study compared the pharmacokinetics (PK), safety, and immunogenicity of the Tocilizumab biosimilar, BAT1806 SC (Tocilizumab biosimilar, Subcutaneous Injection), with...” PMID 41069221 ↗ Oct 2025

“This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who...” NCT01667471 ↗

“This multicenter, randomized, double-blind, placebo-controlled, two-arm, parallel-group study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in...” NCT01532869 ↗

“Currently, there are two available drugs based on human monoclonal antibodies against IL-6 receptor, tocilizumab (RoActemra, Roche) and sarilumab (Kevzara, Sanofi).” NCT04322773 ↗

“Standard surgery using burr-hole procedure, irrigation and drainage combined with Tranexamic acid (Cyklokapron) and Tocilizumab (RoActemra) administration.” NCT03353259 ↗

“This multicenter, open-label, single-arm extension study will evaluate the long-term safety of tocilizumab (RoActemra/Actemra) in participants with RA.” NCT01715831 ↗

“A Study of Administration of RoActemra/Actemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers” NCT01418989 ↗

“RoActemra/Actemra (tocilizumab) in combination with methotrexate versus RoActemra/Actemra monotherapy” NCT01587989 ↗

“RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis” NCT01673919 ↗

“A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis” NCT01245439 ↗

“Tocilizumab [RoActemra®] [ATC: L04AC07] 8 mg/kg i.v. every 4 weeks OR 162 mg s.c every seven days” NCT03100253 ↗

“A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis” NCT01214733 ↗

“MSB11456, US-licensed Actemra® and EU-approved RoActemra® in Healthy Adult Subjects” NCT03282851 ↗

“A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis” NCT01209689 ↗

“Tocilizumab: Roactemra 4-8 mg/kg/month and 162 mg/week” NCT01557374 ↗

“Biological: Tocilizumab (Actemra or RoActemra)” NCT01242488 ↗

“Drug: tocilizumab [RoActemra/Actemra]” NCT00965653 ↗

“Drug: tocilizumab [RoActemra/Actemra]” NCT00754572 ↗

“Tocilizumab (RoActemra®, 20 mg/mL).” NCT06818266 ↗

“tocilizumab [RoActemra/Actemra]” NCT00977106 ↗

“tocilizumab [RoActemra/Actemra]” NCT00891020 ↗

“tocilizumab [RoActemra/Actemra]” NCT01063062 ↗

“tocilizumab [RoActemra/Actemra]” NCT01183598 ↗

“tocilizumab (RoActemra/Actemra)” NCT01664598 ↗

“tocilizumab [RoActemra/Actemra]” NCT00848120 ↗

“tocilizumab [RoActemra/Actemra]” NCT00773461 ↗

“RoActemra/Actemra (tocilizumab)” NCT01326962 ↗

“tocilizumab [RoActemra/Actemra]” NCT01991990 ↗

“tocilizumab [RoActemra/Actemra]” NCT01332994 ↗

“tocilizumab [RoActemra/Actemra]” NCT00883753 ↗

“tocilizumab [RoActemra/Actemra]” NCT01149057 ↗

“tocilizumab [RoActemra/Actemra]” NCT01649804 ↗

“tocilizumab [RoActemra/Actemra]” NCT00951275 ↗

“RoActemra/Actemra (tocilizumab)” NCT01995201 ↗

“tocilizumab [RoActemra/Actemra]” NCT01034397 ↗

“tocilizumab [RoActemra/Actemra]” NCT01730456 ↗

“tocilizumab [RoActemra/Actemra]” NCT01089023 ↗

“tocilizumab [RoActemra/Actemra]” NCT00365001 ↗

“tocilizumab [RoActemra/Actemra]” NCT01878318 ↗

“tocilizumab [RoActemra/Actemra]” NCT01251120 ↗

“tocilizumab [RoActemra/Actemra]” NCT00642460 ↗

“tocilizumab [RoActemra/Actemra]” NCT00106522 ↗

“tocilizumab [RoActemra/Actemra]” NCT01195272 ↗

“tocilizumab [RoActemra/Actemra]” NCT00109408 ↗

“tocilizumab [RoActemra/Actemra]” NCT01727986 ↗

“tocilizumab [RoActemra/Actemra]” NCT01235507 ↗

“tocilizumab [RoActemra/Actemra]” NCT00750880 ↗

“tocilizumab [RoActemra/Actemra]” NCT01010503 ↗

“tocilizumab [RoActemra/Actemra]” NCT01219933 ↗

“tocilizumab [RoActemra/Actemra]” NCT00810277 ↗

“tocilizumab [RoActemra/Actemra]” NCT01610791 ↗

“tocilizumab [RoActemra/Actemra]” NCT00996203 ↗

“Tocilizumab (RoActemra®)” NCT01297699 ↗

“Tocilizumab (RoActemra®)” NCT02779114 ↗

“Tocilizumab (RoACTEMRA®)” NCT03601611 ↗

“tocilizumab [RoActemra]” NCT01254331 ↗

NCT04512001 ↗

NCT05188378 ↗

NCT03651518 ↗

NCT02466581 ↗

NCT05489224 ↗

NCT03282851 ↗
Known as RoActemra/Actemra “RoActemra/Actemra (tocilizumab)” NCT02010216 ↗
Known as TCZ “This is a multi-center, randomized, open label study that will assess the efficacy and safety of ACTEMRA(R) or one of its FDA-approved biosimilars Tocilizumab (TCZ) maintenance...” NCT07108387 ↗
47

“Patients with rheumatoid arthritis for whom biologics had not failed or who did not discontinue methotrexate because of lack of efficacy or tolerability were followed up for 5...” PMID 27909081 ↗ Dec 2016

“OBJECTIVE: Two randomised controlled trials, AMBITION (NCT00109408) and ADACTA (NCT01119859), showed tocilizumab (TCZ) monotherapy superior to methotrexate (MTX) and adalimumab...” PMID 28955499 ↗ Sep 2017

“The interleukin-6 pathway is up-regulated in giant cell arteritis (GCA), Takayasu arteritis (TA), and polymyalgia rheumatica (PMR). We retrospectively assessed the outcomes of...” PMID 22674883 ↗ Nov 2012

“This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab (TCZ) compared with a matching placebo in combination with standard of care...” NCT04320615 ↗

“This multicenter, open-label, single arm, interventional, long-term extension (LTE) study will evaluate the safety and efficacy of tocilizumab (TCZ, RoActemra/Actemra) in...” NCT01734993 ↗

“The efficacy of tocilizumab (TCZ), an anti-interleukin-6 receptor antibody, has not previously been evaluated in a population consisting exclusively of patients with early...” PMID 26511996 ↗ Oct 2015

“Efficacy and safety of tocilizumab (TCZ), an interleukin-6 receptor inhibitor, were demonstrated in juvenile idiopathic arthritis (JIA) with polyarticular course (pJIA) in the...” PMID 29654485 ↗ Apr 2018

“In this context, the investigators treated 11 patients with refractory chronic inflammatory CPPD with tocilizumab (TCZ), an anti-IL-6 receptor (IL-6R) monoclonal antibody.” NCT07254637 ↗

“Tocilizumab (TCZ) is a humanized recombinant monoclonal antibody of the IgG1 immunoglobulin subclass, is directed against soluble or membrane IL-6 receptors (IL-6R).” NCT04363853 ↗

“Patients were randomized to either TNFi (infliximab, INF), anti-IL-6 (tocilizumab, TCZ), CTLA4-Ig (abatacept, ABA) or anti-CD20 (rituximab, RTX) in addition to MTX.” PMID 34792562 ↗ Jul 2022

“patients with systemic juvenile idiopathic arthritis (sJIA) and polyarticular-course juvenile idiopathic arthritis (pcJIA) treated with tocilizumab (TCZ).” PMID 30824645 ↗ Mar 2019

“two different doses of intravenous (IV) infusions of tocilizumab (TCZ), an IL-6 inhibitor, in eyes with NIU using a semi-quantitative FA scoring system.” PMID 33042579 ↗ Oct 2020

“Tranexamic acid (TXA), an antifibrinolytic agent, and tocilizumab (TCZ), an anti-inflammatory agent, represent promising therapeutic candidates.” PMID 42423601 ↗ Jul 2026

“humanized anti-human IL-6 receptor monoclonal antibody tocilizumab (TCZ) either in monotherapy or in combination therapy with methotrexate (MTX)” NCT01120366 ↗

“anti-IL-6 treatment (tocilizumab \[TCZ\]) demonstrated to be very effective in reducing the clinical symptoms and inflammation markers in SchS.” NCT03046381 ↗

“A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)” NCT01904279 ↗

“Tocilizumab (TCZ), humanized monoclonal antibody against IL-6receptor, in the treatment of refractory Uveitis of Behçet's disease (BDU)” NCT03554161 ↗

“Tocilizumab (TCZ) is an anti-human IL-6 receptor monoclonal antibody that inhibits signal transduction by binding sIL-6R and mIL-6R.” NCT04476979 ↗

“Recent studies have shown that tocilizumab (TCZ), an anti-IL-6 receptor monoclonal antibody, is remarkably effective in treating GCA” PMID 41067765 ↗ Oct 2025

“Tocilizumab (TCZ), a monoclonal antibody against the interleukin-6 receptor is an effective new biotherapy for the treatment of RA.” NCT02843789 ↗

“Tocilizumab (TCZ) has demonstrated lung function preservation in 2 randomized controlled trials in early systemic sclerosis (SSc).” PMID 33538094 ↗ May 2021

“Tocilizumab (TCZ) is a humanized anti-IL-6R monoclonal antibody, developed and investigated in several clinical trials in RA.” NCT02765074 ↗

“Participants will receive intravenous (IV) tocilizumab (TCZ) at a dose of 8 mg/kg in addition to standard-of-care treatment.” NCT04363736 ↗

“Tocilizumab (TCZ) is a humanized monoclonal antibody directed against the human interleukin-6 receptor (IL-6R).” NCT01450137 ↗

“subcutaneous tocilizumab (TCZ) in combination with conventional synthetic disease-modifying antirheumatic drugs” PMID 32251060 ↗ Oct 2020

“Tocilizumab (TCZ) significantly suppresses symptoms, however not all patients are protected from joint damage.” PMID 26787505 ↗ Jan 2016

“Tocilizumab (TCZ), an antiinterleukin-6 receptor monoclonal antibody, is clinically beneficial” PMID 24786929 ↗ May 2014

“Experimental arm's patients will obtain TCZ intravenously once every 4 weeks for 28 weeks” NCT03446209 ↗

“Tocilizumab (TCZ) in Combination With Methotrexate (MTX) Versus Tocilizumab Monotherapy” NCT01587989 ↗

“Tocilizumab (TCZ) blocks the receptor for IL-6, inhibiting functions of this cytokine.” PMID 37011013 ↗ Jul 2023

“Patients are treated with infusions of Tocilizumab (TCZ) or placebo for 5 months.” NCT02908217 ↗

“single-dose intravenous infusion of the anti-IL-6 receptor drug Tocilizumab (TCZ)” PMID 33307107 ↗ Dec 2020

“Tocilizumab (TCZ) is a humanized monoclonal antibody against the IL-6 receptor.” PMID 29067495 ↗ Oct 2017

“evaluate the efficacy and safety of tocilizumab (TCZ) compared with a placebo” NCT04372186 ↗

“The Tocilizumab (TCZ) group (case) and Corticosteroid (CS) group (Control).” PMID 33585031 ↗ Feb 2021

“Patients are treated with infusions of Tocilizumab (TCZ) for 3 months.” NCT01713842 ↗

“Tocilizumab (TCZ) monotherapy 8mg/kg 4-weekly for a total of 48 weeks.” NCT04157010 ↗

“The aim of this study was to evaluate tocilizumab (TCZ) as an add-on” PMID 30054122 ↗ Jul 2018

“A drug called tocilizumab (TCZ) has been designed to block IL-6.” NCT00868751 ↗

“Tocilizumab (TCZ) is a humanized anti-human IL-6R antibody” PMID 27236390 ↗ May 2016

“glucocorticoids (GC) and/or tocilizumab (TCZ) known” PMID 37287970 ↗ May 2023

“Tocilizumab (TCZ) in New-onset Type 1 Diabetes” NCT02293837 ↗

“Tocilizumab (TCZ, RO4877533)” NCT01044498 ↗

“tocilizumab (TCZ) s.c.” NCT02287922 ↗

“Tocilizumab (TCZ)” NCT01855789 ↗

“Tocilizumab (TCZ)” NCT02837146 ↗

“Tocilizumab (TCZ)” NCT04335071 ↗
Known as TCZ-SC “OBJECTIVES: This post hoc analysis of the TOZURA study programme evaluated the efficacy and safety of subcutaneous tocilizumab (TCZ-SC) as monotherapy or with concomitant...” PMID 30649524 ↗ Jun 2019
Known as Toc “PURPOSE: This randomized phase-II trial (ClinicalTrials.gov identifier: NCT02767557) compared efficacy of gemcitabine/nab-paclitaxel (Gem/Nab) with or without the...” PMID 40354592 ↗ May 2025
Known as tocilizumab-aazg ClinicalTrials.gov intervention name — accepted as the source's own label NCT06863480 ↗
Known as TYENNE “tocilizumab-aazg (TYENNE)” NCT06863480 ↗
1

NCT07570173 ↗
Action Inhibit “IL-6 receptor inhibition with tocilizumab” PMID 18625622 ↗ Jul 2008
Modality Monoclonal antibody “tocilizumab, an anti-IL-6 receptor monoclonal antibody” PMID 18625622 ↗ Jul 2008
Route Intravenous “tocilizumab given intravenously every other week for 12 weeks” PMID 20112381 ↗ Feb 2010
Target IL6R “tocilizumab, a humanized monoclonal antibody targeting the interleukin (IL)-6 receptor, recently approved for treating RA.” PMID 22491018 ↗ Apr 2012